Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

101

Full text

Free full text

Publication Types

Journal Article

101

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Comparative Study

Clinical Trial

Multicenter Study

Review

Meta-Analysis

Clinical Trial, Phase III

Controlled Clinical Trial

Research Support, N.I.H., Extramural

Systematic Review

Clinical Trial, Phase II

Research Support, U.S. Gov't, P.H.S.

Clinical Trial, Phase I

Network Meta-Analysis

Clinical Trial Protocol

Patient Education Handout

Publication Year

From

Quick links

Individual year

2025

2024

2023

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Irbesartan""[mesh_terms]

102 Results

Searching titles within these results

Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy.

Karly P Garnock-Jones

American journal of cardiovascular drugs : drugs, devices, and other interventions 2013;13(2):141-50

Full Text

Abstract

What is the impact of PRIME on real-life diabetic nephropathy?

L M Ruilope

International journal of clinical practice 2004;58(3):268-76

Full Text

Abstract

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.

George L Bakris, Marianne T Sweetser, Sean Rhyee, Stephen A Huang, Don Foster, Gabriel J Robbie, Yansong Cheng, Sarah Casey, Jorg Taubel, David J Webb, Akshay S Desai

The New England journal of medicine 2023;389(3):228-238

Full Text

Abstract

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

Charles E Alpers, Radko Komers, Muh Geot Wong, James Tumlin, Hernán Trimarchi, Vladimir Tesar, Brad Rovin, William Rote, Jai Radhakrishnan, Vlado Perkovic, Irene L Noronha, Alex Mercer, Kenneth Lieberman, Laura A Kooienga, Howard Trachtman, Donald Kohan, Gianna M Kirsztajn, Jula K Inrig, Hiddo J L Heerspink, Loreto Gesualdo, Ulysses Diva, Gaia Coppock, Dong-Wan Chae, Pietro Canetta, Stewart Bieler, Jonathan Barratt, Michelle N Rheault

The New England journal of medicine 2024;389(26):2436-2445

Full Text

Abstract

Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.

E Bragulat, M Larrousse, A Coca, A de la Sierra

British journal of biomedical science 2004;60(4):191-6

Full Text

Abstract

Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

Mattia Rizzi, Giacomo D Simonetti, Rodo O von Vigier, Emilio Fossali, Martin Konrad, Mario G Bianchetti

Pediatric nephrology (Berlin, Germany) 2006;21(10):1480-2

Free Full Text

Abstract

Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.

Zhen Lei, Ting Li, Ying Zuo

Pharmacological research 2020;146():104286

Full Text

Abstract

Drug interactions with irbesartan.

M R Marino, N N Vachharajani

Clinical pharmacokinetics 2002;40(8):605-14

Full Text

Abstract

Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

Gregory Y H Lip, Deirdre A Lane

The American journal of medicine 2010;123(9):785-9

Full Text

Abstract

Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.

Lorena González, Urtzi Akesolo, Rosa M Jiménez, Rosa M Alonso

Electrophoresis 2002;23(2):223-9

Full Text

Abstract

Twenty-Four-Hour Urine α -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs.

Nikolaos V Kafkas, Dimitrios Tousoulis, Konstantinos P Toutouzas, Maria I Markou, Gregory P Vyssoulis, Charalampos I Liakos

Journal of clinical hypertension (Greenwich, Conn.) 2017;18(10):1000-1006

Free Full Text

Abstract

Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).

Robert G Hart, Stuart J Connolly, Oscar Benavente, Mukul Sharma, Lesly A Pearce, Kanjana S Perera

The American journal of cardiology 2019;121(5):584-589

Full Text

Abstract

Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.

John J V McMurray, Peter E Carson, Michel Komajda, Robert McKelvie, Michael R Zile, Agata Ptaszynska, Christoph Staiger, J Mark Donovan, Barry M Massie

European journal of heart failure 2008;10(2):149-56

Free Full Text

Abstract

Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study.

Tetsuro Yoshida, Tomohiro Katsuya, Toshihiko Shiraiwa, Kayo Yamagiwa, Kazuaki Uchiyama, Hajime Ishii, Hiroshi Kanegae, Naoko Tomitani, Kazuomi Kario, Kiyomi Kanda, Satoshi Hoshide, Shinji Hasegawa

Circulation journal : official journal of the Japanese Circulation Society 2018;81(7):948-957

Free Full Text

Abstract

The value of irbesartan in the management of hypertension.

Caroline Hacker, Olaf Pirk, Nisha Desai, Isabelle Durand-Zaleski, Peter Bramlage

Expert opinion on pharmacotherapy 2009;10(11):1817-31

Full Text

Abstract

Results: 1 – 15 / 102

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Irbesartan""[mesh_terms]

Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy.

What is the impact of PRIME on real-life diabetic nephropathy?

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.

Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.

Drug interactions with irbesartan.

Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.

Twenty-Four-Hour Urine α -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs.

Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).

Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.

Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study.

The value of irbesartan in the management of hypertension.

Results for
""Irbesartan""[mesh_terms]

Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study.